[go: up one dir, main page]

WO2006075094A3 - Derives de la purine, compositions les contenant et leurs utilisation contre le cancer - Google Patents

Derives de la purine, compositions les contenant et leurs utilisation contre le cancer Download PDF

Info

Publication number
WO2006075094A3
WO2006075094A3 PCT/FR2006/000065 FR2006000065W WO2006075094A3 WO 2006075094 A3 WO2006075094 A3 WO 2006075094A3 FR 2006000065 W FR2006000065 W FR 2006000065W WO 2006075094 A3 WO2006075094 A3 WO 2006075094A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
compositions containing
purine derivatives
against cancer
derivatives compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/000065
Other languages
English (en)
Other versions
WO2006075094A2 (fr
Inventor
Chantal Carrez
Florence Fassy
Patrick Mailliet
Fabienne Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to JP2007550815A priority Critical patent/JP2008526930A/ja
Priority to EP06709072A priority patent/EP1841769A2/fr
Publication of WO2006075094A2 publication Critical patent/WO2006075094A2/fr
Publication of WO2006075094A3 publication Critical patent/WO2006075094A3/fr
Priority to US11/773,572 priority patent/US20080119467A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dérivés de la purine de formule (IA1) ou (IB1):, compositions les contenant et utilisation comme médicaments, en particulier en oncologie, dans laquelle Y et Z représentent N ou CH ; X représente un atome d'halogène ; dans (IA), A représente N ou CH et dans (IB), A représente O, S, NH, CH2 ou CHR ; B représente O, S, NR’, CH2 ou CHR’ ; R représente H ou alkyle ; R’ représente H, alkyle, alkényle, alkynyle ; (CH2)n-aryle ou hétéroaryle ;-CH(aryle)2; C(Z)-aryle ou hétéroaryle ; éventuellement substitués ; n= 0, 1 , 2 ; Z représente O, S ou NR'.
PCT/FR2006/000065 2005-01-13 2006-01-11 Derives de la purine, compositions les contenant et leurs utilisation contre le cancer Ceased WO2006075094A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007550815A JP2008526930A (ja) 2005-01-13 2006-01-11 プリン誘導体、プリン誘導体を含有する組成物およびこの使用
EP06709072A EP1841769A2 (fr) 2005-01-13 2006-01-11 Derives de la purine, compositions les contenant et leurs utilisation contre le cancer
US11/773,572 US20080119467A1 (en) 2005-01-13 2007-07-05 Purine Derivatives, Compositions Containing Them and Use Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500349 2005-01-13
FR0500349A FR2880626B1 (fr) 2005-01-13 2005-01-13 Derives de la purine, compositions les contenant et utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/773,572 Continuation US20080119467A1 (en) 2005-01-13 2007-07-05 Purine Derivatives, Compositions Containing Them and Use Thereof

Publications (2)

Publication Number Publication Date
WO2006075094A2 WO2006075094A2 (fr) 2006-07-20
WO2006075094A3 true WO2006075094A3 (fr) 2006-12-07

Family

ID=34954725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000065 Ceased WO2006075094A2 (fr) 2005-01-13 2006-01-11 Derives de la purine, compositions les contenant et leurs utilisation contre le cancer

Country Status (6)

Country Link
US (1) US20080119467A1 (fr)
EP (1) EP1841769A2 (fr)
JP (1) JP2008526930A (fr)
AR (1) AR052454A1 (fr)
FR (1) FR2880626B1 (fr)
WO (1) WO2006075094A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101623B2 (en) 2007-10-11 2012-01-24 Astrazeneca Ab Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
US9402847B2 (en) 2011-04-01 2016-08-02 Astrazeneca Ab Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
US9737540B2 (en) 2011-11-30 2017-08-22 Astrazeneca Ab Combination treatment of cancer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ES2878130T3 (es) 2006-04-25 2021-11-18 Astex Therapeutics Ltd Derivados de purina y deazapurina como compuestos farmacéuticos
CA2660114A1 (fr) * 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Derives d'azacycloalcane en tant qu'inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
WO2008075007A1 (fr) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Composé bicyclohétéroarylés substitué par morpholino et leur utilisation en tant qu'agents anti-cancer
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
EP2923734B1 (fr) * 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Analogues de purines et leur utilisation en tant qu'agents immunosuppresseurs
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013182612A1 (fr) * 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Inhibiteurs de transport du glucose
ES2833473T3 (es) * 2015-04-21 2021-06-15 Chengdu Zenitar Biomedical Tech Co Ltd Derivados de purinil-N-hidroxil pirimidin formamida, método de preparación y uso de los mismos
CZ306987B6 (cs) * 2015-10-26 2017-11-01 Ústav experimentální botaniky AV ČR, v. v. i. 2,6-disubstituované puriny pro použití jako léčiva a farmaceutické přípravky je obsahující
CZ306434B6 (cs) * 2015-10-26 2017-01-18 Ústav experimentální botaniky AV ČR, v. v. i. 2,6-disubstituované puriny pro použití jako léčiva, a farmaceutické přípravky
EP3962485A4 (fr) * 2019-05-02 2022-12-28 University Of Virginia Patent Foundation Analogues de (pipéridin-1-yl)aryle substitués pour la modulation de l'activité de l'avil

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020078A1 (fr) * 1992-04-03 1993-10-14 The Upjohn Company Amines bicycliques-heterocycliques efficaces pharmaceutiquement
WO1998005235A1 (fr) * 1996-08-01 1998-02-12 A.W. Faber-Castell Unternehmensverwaltung Gmbh & Co. Crayon a mine tendre
WO1999002162A1 (fr) * 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Derives de purine inhibant la kinase dependant de la cycline
WO1999065909A1 (fr) * 1998-06-19 1999-12-23 Pfizer Products Inc. COMPOSES DE PYRROLO[2,3-d]PYRIMIDINE
WO2000044750A1 (fr) * 1999-02-01 2000-08-03 Cv Therapeutics, Inc. INHIBITEURS PURIQUES DES KINASES 2 ET IλB-α DEPENDANTES DES CYCLINES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7951592B2 (en) * 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020078A1 (fr) * 1992-04-03 1993-10-14 The Upjohn Company Amines bicycliques-heterocycliques efficaces pharmaceutiquement
WO1998005235A1 (fr) * 1996-08-01 1998-02-12 A.W. Faber-Castell Unternehmensverwaltung Gmbh & Co. Crayon a mine tendre
WO1999002162A1 (fr) * 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Derives de purine inhibant la kinase dependant de la cycline
WO1999065909A1 (fr) * 1998-06-19 1999-12-23 Pfizer Products Inc. COMPOSES DE PYRROLO[2,3-d]PYRIMIDINE
WO2000044750A1 (fr) * 1999-02-01 2000-08-03 Cv Therapeutics, Inc. INHIBITEURS PURIQUES DES KINASES 2 ET IλB-α DEPENDANTES DES CYCLINES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHNSTON, THOMAS P. ET AL: "Synthesis of potential anticancer agents. XVI. S-Substituted derivatives of 6-mercaptopurine", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 80, 6265-71 CODEN: JACSAT; ISSN: 0002-7863, 1958, XP009052623 *
PANAGOPOULOS, KIM ET AL: "Synthesis of potent anticancer agents. I. 6-(1-Pyrrolidyl)purines, 6-(1-piperidyl)purines, and their nucleosides", ARZNEIMITTEL-FORSCHUNG , 15(3), 204-7 CODEN: ARZNAD; ISSN: 0004-4172, 1965, XP009052694 *
THOMPSON, ROBERT D. ET AL: "N6,9-Disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor", JOURNAL OF MEDICINAL CHEMISTRY , 34(9), 2877-82 CODEN: JMCMAR; ISSN: 0022-2623, 1991, XP002048672 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101623B2 (en) 2007-10-11 2012-01-24 Astrazeneca Ab Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
US9492453B2 (en) 2007-10-11 2016-11-15 Astrazeneca Ab Protein kinase B inhibitors
US10059714B2 (en) 2007-10-11 2018-08-28 Astrazeneca Ab Protein kinase B inhibitors
US10654855B2 (en) 2007-10-11 2020-05-19 Astrazeneca Ab Protein kinase B inhibitors
US11236095B2 (en) 2007-10-11 2022-02-01 Astrazeneca Ab Protein kinase B inhibitors
US11760760B2 (en) 2007-10-11 2023-09-19 Astrazeneca Ab Protein kinase B inhibitors
US12252495B2 (en) 2007-10-11 2025-03-18 Astrazeneca Ab Protein kinase B inhibitors
US9402847B2 (en) 2011-04-01 2016-08-02 Astrazeneca Ab Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
US9737540B2 (en) 2011-11-30 2017-08-22 Astrazeneca Ab Combination treatment of cancer

Also Published As

Publication number Publication date
JP2008526930A (ja) 2008-07-24
FR2880626A1 (fr) 2006-07-14
FR2880626B1 (fr) 2008-04-18
US20080119467A1 (en) 2008-05-22
EP1841769A2 (fr) 2007-10-10
AR052454A1 (es) 2007-03-21
WO2006075094A2 (fr) 2006-07-20

Similar Documents

Publication Publication Date Title
WO2006075094A3 (fr) Derives de la purine, compositions les contenant et leurs utilisation contre le cancer
TW200800999A (en) Novel compounds
TW200801003A (en) Novel compounds
SE0202539D0 (sv) Compounds
WO2005021544A3 (fr) Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
WO2007048064A3 (fr) Aminopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
SE0401971D0 (sv) Piperidne derivatives
WO2010003475A8 (fr) Nouveaux dérivés de pyrrolidine utilisés comme inhibiteurs de la metap-2
UA103873C2 (ru) Гетероарильные производные мочевины как ингибиторы р38 и их применение
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
TW200745084A (en) Novel compounds
NO20076333L (no) Anvendelse av thiazolderivater og analoge i behandling av kreft
SE0401762D0 (sv) Novel compounds
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2008077885A3 (fr) Nouveaux composés
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2006116733A3 (fr) Inhibiteurs des proteines kinases
TW200639156A (en) New compounds
TW200635917A (en) Novel compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007550815

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006709072

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006709072

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11773572

Country of ref document: US